Travere Therapeutics (TVTX) Accounts Payables (2011 - 2026)

Travere Therapeutics has reported Accounts Payables for 16 years, with the latest figure at $12.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 16.01% year-over-year to $12.9 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (down 16.01% YoY), and the FY2025 full-year result was $24.8 million, up 5.38% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.9 million, down from $24.8 million in the prior quarter.
• The five-year high for Accounts Payables was $41.7 million in Q4 2023, with the low at $11.8 million in Q2 2022.
• Historically, Accounts Payables has averaged $20.3 million across 5 years, with a median of $18.4 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 141.04% — and 2024, when it sank 43.53%.
• Travere Therapeutics' Accounts Payables stood at $17.3 million in 2022, then jumped by 141.04% to $41.7 million in 2023, then slumped by 43.53% to $23.5 million in 2024, then increased by 5.38% to $24.8 million in 2025, then tumbled by 47.94% to $12.9 million in 2026.
• The last three Accounts Payables figures came in at $12.9 million (Q1 2026), $24.8 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.